Table 2a.

Treatment emergent adverse events that occurred in at least 3 subjects.

	IP SPP (100 mg/m2) + SOC (N = 7)	IP SPP (200 mg/m2) + SOC (N = 3)	Total (N = 10)
Nausea	3 (42.9%)	3 (100%)	6 (60.0%)
Procedural pain	4 (57.1%)	2 (66.7%)	6 (60.0%)
Vomiting	2 (28.6%)	2 (66.7%)	4 (40.0%)
Fatigue	3 (42.9%)	1 (33.3%)	4 (40.0%)
Leukocytosis	2 (28.6%)	1 (33.3%)	3 (30.0%)
Constipation	2 (28.6%)	1 (33.3%)	3 (30.0%)
Urinary tract infection	2 (28.6%)	1 (33.3%)	3 (30.0%)
Hypokalaemia	2 (28.6%)	1 (33.3%)	3 (30.0%)